semaglutide fort worth - Southfork Pharmacy dallas semaglutide nausea law office

In August 2025, Novo Nordisk announced that the FDA has approved WEGOVY as the first GLP-1 receptor agonist for adults with Metabolic Dysfunction-associated Steatohepatitis (MASH) who have moderate to advanced fibrosis, excluding cirrhosis, in combination with diet and exercise

Dual E-Selectin/CXCR4 Antagonist GMI-1359 Exerts Efficient Anti-Leukemia Effects in a FLT3 ITD Mutated Acute Myeloid Leukemia Patient-Derived Xenograft Murine Model

A randomised trial showed a consistent signal of increased risk, especially with higher doses, longer use, and when rapid weight loss occurs

They need you to hold space for complexity, fear, and agency